<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01562678</url>
  </required_header>
  <id_info>
    <org_study_id>2011P000280</org_study_id>
    <nct_id>NCT01562678</nct_id>
  </id_info>
  <brief_title>Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI</brief_title>
  <official_title>Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to help us understand the effects of diabetes medication&#xD;
      Liraglutide on weight loss and hunger. The investigators have already determined what the&#xD;
      highest tolerated dose of Liraglutide is through earlier human research studies. Liraglutide&#xD;
      was approved by the FDA in January 2010 for treatment of diabetes.&#xD;
&#xD;
      The investigators will also study the following:&#xD;
&#xD;
        1. The impact of Liraglutide on brain responses to food&#xD;
&#xD;
        2. It's effect on physiological and mental performance&#xD;
&#xD;
        3. If its effect on the brain differs among obese and lean diabetic subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo controlled, cross-over, double-blinded study to assess the&#xD;
      effects of liraglutide on brain activation in areas involved in cognitive control and reward&#xD;
      during food visualization.&#xD;
&#xD;
      Study participation will span approximately 1.5-2 months. Subjects will learn to&#xD;
      self-administer the medication and will have a total of 8 study visits plus one screening&#xD;
      visit. The visits will include the following tests/procedures:&#xD;
&#xD;
        1. Vital signs (blood pressure, temperature, heart rate, breathing rate)&#xD;
&#xD;
        2. Height, weight and other body measurements like waist&#xD;
&#xD;
        3. Blood tests&#xD;
&#xD;
        4. Urine pregnancy test (women only)&#xD;
&#xD;
        5. Electrocardiogram (EKG)&#xD;
&#xD;
        6. Medical history&#xD;
&#xD;
        7. Physical exam&#xD;
&#xD;
        8. Body Composition tests&#xD;
&#xD;
        9. Study logs to record food intake and blood sugar&#xD;
&#xD;
       10. functional MRI&#xD;
&#xD;
      We plan to recruit a total of 24 subjects to be treated with placebo and liraglutide. We&#xD;
      propose to enroll 12 obese diabetic (type 2) and 12 lean diabetic (type 2) subjects. Equal&#xD;
      numbers of men and women will be enrolled and the randomization will block for gender.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization</measure>
    <time_frame>18 days of Liraglutide or placebo treatment</time_frame>
    <description>Effect size (region of interest z-scores, derived from z-maps of the brain) shown below is the difference in parietal cortex activation to highly desirable (high fat or high calorie, e.g. cakes, pies, fries) versus less desirable (low fat or low calorie, e.g. vegetables, fruits) food cues for each treatment condition (liraglutide or placebo) at the end of the treatment period.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Diabetes</condition>
  <condition>Effects of Liraglutide Administration on Brain Activity</condition>
  <condition>Weight Loss</condition>
  <condition>Hunger</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>In the experimental arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject Liraglutide once per day for 18 days. Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week.</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In the placebo arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject placebo once per day for 18 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects will be men and women between the ages of 18 and 65. The following table list&#xD;
        inclusion criteria for each group (lean diabetic and obese diabetic). Subjects must meet&#xD;
        either HbA1c or fasting plasma glucose (FPG) criteria.&#xD;
&#xD;
        Lean diabetic:&#xD;
&#xD;
        BMI: 18-25 kg/m2 HbA1c: &lt; 8.9% Fasting plasma glucose: &lt;250 mg/dL Other inclusion criteria:&#xD;
        On dietary modification and/or metformin&#xD;
&#xD;
        Obese diabetic:&#xD;
&#xD;
        BMI: &gt;27 kg/m2 HbA1c: &lt; 8.9% Fasting plasma glucose: &lt;250 mg/dL Other inclusion criteria:&#xD;
        On dietary modification and/or metformin&#xD;
&#xD;
        Additionally, women participants must use double barrier methods to prevent pregnancy&#xD;
        (diaphragm with intravaginal spermicide, cervical cap, male or female condom with&#xD;
        spermicide). If a woman suspects that she has become pregnant at any time or does not use&#xD;
        one of the contraceptive methods recommended by the investigator, she must notify the study&#xD;
        staff. If a woman becomes pregnant, she will be withdrawn from the study. The study staff&#xD;
        will follow the progress of her pregnancy and the birth of her child.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled diabetes (HbA1c&gt;8.9%, or FPG&gt;250 mg/dL)&#xD;
&#xD;
          2. Women who are breastfeeding, pregnant, or wanting to become pregnant.&#xD;
&#xD;
          3. Women using IUD&#xD;
&#xD;
          4. Any change in the dosage of hormonal contraceptive medications (birth control pills,&#xD;
             implanon). Subjects should remain on same medication/ same dose during the time of the&#xD;
             entire study.&#xD;
&#xD;
          5. Moderate (creatinine clearance of 30-59 ml/min) and severe renal impairment&#xD;
             (creatinine clearance below 30 ml/min) and end-stage renal disease&#xD;
&#xD;
          6. Moderate, or severe hepatic impairment&#xD;
&#xD;
          7. Hypersensitivity to the active substance or any of the excipients in liraglutide&#xD;
&#xD;
          8. History of diabetic ketoacidosis&#xD;
&#xD;
          9. Congestive heart failure&#xD;
&#xD;
         10. Inflammatory conditions like inflammatory bowel disease, Rheumatoid arthritis etc&#xD;
&#xD;
         11. Gastroparesis&#xD;
&#xD;
         12. Pancreatitis&#xD;
&#xD;
         13. Gallstones- as they may cause increased risk of pancreatitis&#xD;
&#xD;
         14. Alcohol consumption- the maximum quantity for men is 140g-210g per week. For women,&#xD;
             the range is 84g-140g per week or drinking as consuming no more than two drinks a day&#xD;
             for men and one for women. Alcohol can cause increased risk of pancreatitis and&#xD;
             hypoglycemia.&#xD;
&#xD;
         15. Untreated thyroid disease like hypothyroidism or hyperthyroidism&#xD;
&#xD;
         16. Subjects taking the following medications: warfarin, steroids (inhaled or systemic due&#xD;
             to reduced hypoglycemic effect), and subjects on other hormones (LHRH analogs etc).&#xD;
&#xD;
         17. Subjects on any oral anti-diabetic agent except metformin&#xD;
&#xD;
         18. Personal or family history of MEN II or medullary thyroid cancer&#xD;
&#xD;
         19. Subjects with any type of bioimplant activated by mechanical, electronic, or magnetic&#xD;
             means (e.g. cochlear implants, pacemakers, neuron or biostimulators, electronic&#xD;
             infusion pumps, etc.)&#xD;
&#xD;
         20. Subjects with any type of metallic implant that could potentially be displaced or&#xD;
             damaged during MRI, such as aneurysm clips, metallic skull plates, surgical implants&#xD;
             etc. or metal containing tattoos&#xD;
&#xD;
         21. Anxiety and/or claustrophobia&#xD;
&#xD;
         22. Uncontrolled cardiac impairment, circulatory impairment, or inability to perspire&#xD;
             (poor thermoregulatory function)&#xD;
&#xD;
         23. Significant sensory or motor impairment&#xD;
&#xD;
         24. Epilepsy, particularly photo-sensitive epilepsy, which may place the individual at a&#xD;
             higher risk for adverse events during fMRI scanning with visual stimulation&#xD;
&#xD;
         25. Subjects with neurological problems which may interfere with or complicate testing&#xD;
             (e.g. presence of titubation)&#xD;
&#xD;
         26. Body weight above the limitation of the MRI scanning table (330lbs/150 Kg) or body&#xD;
             dimensions that could difficult the performance of the scan.&#xD;
&#xD;
         27. Subjects who cannot adhere to the experimental protocol for any reason&#xD;
&#xD;
         28. Anemia with Hgb less than 10&#xD;
&#xD;
         29. Uncontrolled infectious diseases (e.g. HIV, hepatitis, chronic infections etc)&#xD;
&#xD;
         30. Any uncontrolled endocrine condition, e.g Cushing's, Acromegaly, etc&#xD;
&#xD;
         31. Any cancers or lymphoma&#xD;
&#xD;
         32. Eating disorders like anorexia, bulimia&#xD;
&#xD;
         33. Severe hypertriglyceridemia (triglycerides &gt;500 mg/dl)&#xD;
&#xD;
         34. Weight loss surgery or gastrectomy&#xD;
&#xD;
         35. Any changes in medications that affect brain function, e.g. anti-depressants,&#xD;
             anti-psychotics, anti-anxiety, anti-seizure medications, antihypertensives etc&#xD;
             (subjects should remain on same medication/ same dose during the time of the entire&#xD;
             study).&#xD;
&#xD;
         36. Irregular periods, defined as cycle length less than 22 days or more than 40 days.&#xD;
&#xD;
         37. Any change in smoking status.&#xD;
&#xD;
         38. Vegetarians- as food images presented will include numerous non-vegetarian items and&#xD;
             thus will not be appealing as high calorie food items.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos Mantzoros, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bidmc.org/Research/Departments/Medicine/Divisions/Endocrinology/Laboratories/MantzorosLab.aspx</url>
    <description>Mantzoros Lab Website</description>
  </link>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>March 22, 2012</study_first_submitted>
  <study_first_submitted_qc>March 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2012</study_first_posted>
  <results_first_submitted>December 22, 2015</results_first_submitted>
  <results_first_submitted_qc>April 26, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 31, 2017</results_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Christos Mantzoros</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>fMRI</keyword>
  <keyword>Liraglutide</keyword>
  <keyword>diabetes</keyword>
  <keyword>GLP-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liraglutide First, Then Placebo</title>
          <description>14 participants were randomized to receive Liraglutide and then were cross-overed to receive placebo</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Liraglutide</title>
          <description>14 participants were randomized to receive Placebo and then were cross-overed to receive Liraglutide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liraglutide First, Then Placebo</title>
          <description>14 participants were randomized to receive Liraglutide and then were cross-overed to receive placebo</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then Liraglutide</title>
          <description>14 participants were randomized to receive Placebo and then were cross-overed to receive Liraglutide</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="10.5"/>
                    <measurement group_id="B2" value="52.5" spread="10.5"/>
                    <measurement group_id="B3" value="52.5" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization</title>
        <description>Effect size (region of interest z-scores, derived from z-maps of the brain) shown below is the difference in parietal cortex activation to highly desirable (high fat or high calorie, e.g. cakes, pies, fries) versus less desirable (low fat or low calorie, e.g. vegetables, fruits) food cues for each treatment condition (liraglutide or placebo) at the end of the treatment period.</description>
        <time_frame>18 days of Liraglutide or placebo treatment</time_frame>
        <population>Participants with incomplete MRI scans were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Liraglutide</title>
            <description>Liraglutide: In the experimental phase of this randomized, placebo-controlled, cross-over, double-blinded study to assess the effects of liraglutide, subjects started the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week. This sequence may have occurred for their first phase or second phase (placebo was the other phase).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: In the placebo phase of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide, subjects will self-inject placebo once per day for 18 days. Participants had this first or second (liraglutide was the other phase).</description>
          </group>
        </group_list>
        <measure>
          <title>Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization</title>
          <description>Effect size (region of interest z-scores, derived from z-maps of the brain) shown below is the difference in parietal cortex activation to highly desirable (high fat or high calorie, e.g. cakes, pies, fries) versus less desirable (low fat or low calorie, e.g. vegetables, fruits) food cues for each treatment condition (liraglutide or placebo) at the end of the treatment period.</description>
          <population>Participants with incomplete MRI scans were excluded from the analysis.</population>
          <units>z-scores of activation in cortex</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.27"/>
                    <measurement group_id="O2" value="0.53" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study (4 visits in each phase of liraglutide and placebo).</time_frame>
      <desc>There was a systematic assessment of adverse events at each visit (Days 0, 7, 14, and 17) by an MD who asked detailed medical questions and did a physical exam, plus through the use of visual analog scales administered 3 times per day where participants answered on a 10cm line questions such as &quot;How nauseous do you feel right now?&quot;</desc>
      <group_list>
        <group group_id="E1">
          <title>Liraglutide</title>
          <description>14 participants were randomized to receive Liraglutide and then were cross-overed to receive placebo and 14 participants were randomized to receive Placebo and then were cross-overed to receive Liraglutide</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>14 participants were randomized to receive Placebo and then were cross-overed to receive Liraglutide and 14 participants were randomized to receive Liraglutide and then were cross-overed to receive placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christos Mantzoros</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-667- 8630</phone>
      <email>cmantzor@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

